Zydus receives tentative approval from USFDA for Colchicine Tablets

Zydus receives tentative approval from USFDA for Colchicine Tablets

Zydus Cadila has received the tentative approval from the USFDA to market Colchicine Tablets USP (US RLD – ColcyrsTM), 0.6 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. This medication is used to prevent or treat attacks of gout (also called gouty arthritis). This condition is caused by high uric acid levels in the blood. An attack of gout occurs when uric acid causes inflammation (pain, redness, swelling, and heat) in a joint. This medication is also used to prevent attacks of pain in the abdomen, chest or joints caused by a genetic auto-inflammatory disease (called as familial Mediterranean fever). The group now has 223 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.